General
Preferred name
FLAVOXATE
Synonyms
FLAVOXATE HYDROCHLORIDE ()
Flavoxato ()
DW61 ()
Rec-7-0040 ()
Flavoxate HCl ()
NSC-114649 ()
Flavoxate (hydrochloride) ()
Flavoxate ()
Urispas 200 ()
Urispas ()
DW-61 ()
Bladuril ()
Flavoxate-d5 ()
P&D ID
PD009777
CAS
3717-88-2
15301-69-6
2748541-85-5
Tags
available
drug
Approved by
FDA
First approval
1970
Drug Status
approved
Drug indication
Urgency
Nocturia
Dysuria
Suprapubic pain
Relaxant (smooth muscle)
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Marketed formulations may contain flavoxate hydrochloride (PubChem CID 441345). (GtoPdb)
DESCRIPTION Flavoxate is an anticholinergic with antimuscarinic effects. Its muscle relaxant properties may be due to a direct action on the smooth muscle rather than by antagonizing muscarinic receptors. (BOC Sciences Bioactive Compounds)
Compound Sets
22
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
55
Properties
(calculated by RDKit )
Molecular Weight
391.18
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
0
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
3
cLogP
4.41
TPSA
59.75
Fraction CSP3
0.33
Chiral centers
0.0
Largest ring
6.0
QED
0.6
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Neuroscience
GPCR/G protein
Membrane Transporter/Ion Channel
Metabolic Enzyme/Protease
Neuronal Signaling
Target
mAChR
CHRM1, CHRM2
Calcium Channel
Phosphodiesterase (PDE)
AChR
Indication
urinary incontinence, interstitial cystitis (IC), urethritis, prostatitis
MOA
acetylcholine receptor antagonist
Therapeutic Class
Parasympatholytics
Source data